Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
On Tuesday, Incyte Corporation INCY reported second-quarter revenue of $1.04 billion, up from $954.6 million a year ago, beating the consensus of $1.03 billion.
Incyte Corporation (INCY) Q2 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q2 2024 Earnings Conference Call July 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Barry Flannelly - General Manager, North America Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Kripa Devarakonda - Truist Securities Paul Jeng - Guggenheim Partners Brian Abrahams - RBC Capital Markets Vikram Purohit - Morgan Stanley David Lebowitz - Citi Eric Schmidt - Cantor Fitzgerald James Shin - Deutsche Bank Jessica Fye - JPMorgan Chase Jay Olson - Oppenheimer & Company Evan Seigerman - BMO Capital Markets Reni Benjamin - Citizens JMP Andrew Berens - Leerink Partners Gavin Clark-Gartner - Evercore ISI Salveen Richter - Goldman Sachs Operator Hello, and welcome to the Incyte Second Quarter 2024 Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.
Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
Incyte (INCY) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of $0.78. This compares to earnings of $0.99 per share a year ago.
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCY or MYGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
Cathie Wood was the hottest money manager in the game in 2020. Her Ark Invest family of funds offered investors blistering returns on their money.
Incyte: The Worst Has Been Avoided
In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $750 million. Sales of Opzelura, one of the company's gems, totaled $85.7 million in the first quarter of 2024, up 51.4% year-on-year.
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
